The current verified maximum human lifespan is 122 years and 164 days, set by Jeanne Calment of France, who died in 1997. Most scientists place the biological ceiling between 120 and 150 years, though reaching 150 would require breakthroughs that do not yet exist. Fewer than 100 people alive today are verified to be 110 or older.
What Science Has Actually Confirmed About How Long Humans Can Live
The verified upper bound for human lifespan, meaning the longest age any individual has reached with documented evidence, currently stands at 122 years. Researchers draw a clear line between lifespan (the maximum age reached by any individual) and life expectancy (the average age a population reaches), two concepts that are frequently confused in public discussions. The average U.S. life expectancy as of 2024 sits at approximately 79.3 years, a figure that is far removed from the biological ceiling.
A landmark 2016 study from Albert Einstein College of Medicine analyzed death records from more than 40 countries and concluded that maximum reported ages at death plateaued at around 115 years beginning in the 1990s. This study, published in Nature, argued that human lifespan has a hard, fixed limit and that the plateau in extreme ages suggests the body hits an unavoidable ceiling. The research remains one of the most cited papers in the entire field of longevity science.
Not everyone in the scientific community agrees with that conclusion. Demographers at the Institut national d’études démographiques in France have argued that mortality rates do not inevitably and permanently accelerate after age 110 and that no definitive mathematical ceiling has been proven. The disagreement between these camps is genuine and ongoing, with new data continuing to surface on both sides of the debate.
Jeanne Calment and the Record That Has Stood for Nearly 30 Years
Jeanne Calment holds the Guinness World Record as the oldest person whose age has been independently and rigorously verified. Born on February 21, 1875, in Arles, France, she died on August 4, 1997, at an age of 122 years and 164 days. No other individual in recorded human history has been verified to a comparable age.
Enter your age and sex in our calculator to find out your life expectancy, and the likelihood of you living to be 100 years old.
A group of demographers raised questions about Calment’s identity in 2018, suggesting that her daughter may have assumed her identity following her death to avoid estate taxes. However, multiple independent investigations, including a review by the Russian Academy of Sciences and a separate analysis by a team of French researchers, concluded that the original record is authentic. The alternative theory was found to lack sufficient supporting evidence.
The second-oldest verified person on record was Sarah Knauss of the United States, who lived to 119 years and 97 days before her death in 1999. The gap between Calment’s record and the second-place holder spans more than three full years, a difference so large that it makes Calment’s case extraordinary even by the standards of extreme old age.
Supercentenarians: The World’s Rarest Age Group
Supercentenarians are individuals who have reached age 110 or older, representing the outermost tail of the human age distribution. At any given time, researchers estimate that fewer than 100 people worldwide qualify as supercentenarians, making this group smaller than almost any other demographic category that scientists track.
| Rank | Name | Country | Age at Death | Year of Death |
|---|---|---|---|---|
| 1 | Jeanne Calment | France | 122 years, 164 days | 1997 |
| 2 | Sarah Knauss | United States | 119 years, 97 days | 1999 |
| 3 | Lucile Randon | France | 118 years, 340 days | 2023 |
| 4 | Nabi Tajima | Japan | 117 years, 260 days | 2018 |
| 5 | Marie-Louise Meilleur | Canada | 117 years, 230 days | 1998 |
Data reliability is a persistent problem in this field. Age fraud, defined as cases where individuals or families have claimed greater ages than documentation supports, has been recorded across multiple countries with weak historical birth registry systems. A 2019 study published in PLOS ONE found substantial evidence that many extreme age claims from countries with poor civil record-keeping are likely inflated, and that the true number of accurately verified supercentenarians is far smaller than publicly claimed figures suggest.
In the United States, the availability of Social Security death records and birth certificates has made verification more reliable. The oldest verified American who ever lived remains Sarah Knauss at 119 years, and researchers at the Gerontology Research Group (a nonprofit organization dedicated to tracking and verifying extreme old age) estimate that roughly 30 to 40 Americans are verifiably 110 or older at any given time.
Why Cells Cannot Keep Dividing: The Core Biology of Aging
Cellular senescence is the process by which cells permanently stop dividing and begin secreting inflammatory proteins that damage surrounding tissue over time. This biological mechanism is one of the primary drivers of physical aging and is a central reason why organs gradually lose function across the human lifespan. As senescent cells accumulate in tissues throughout the body, immune response weakens, repair slows, and the risk of age-related disease rises sharply.
The Hayflick Limit, discovered by cell biologist Leonard Hayflick in 1961, describes the maximum number of times a human cell can divide before permanently ceasing replication. Most human somatic cells (non-reproductive body cells) divide approximately 50 to 70 times before reaching this limit. Each division shortens the telomeres, which are the protective caps on the ends of chromosomes that function similarly to the plastic tips on shoelaces, and once telomeres become critically short, the cell enters senescence or dies.
Mitochondrial dysfunction is a second major contributor to aging. Mitochondria are the organelles inside cells responsible for generating energy, and they accumulate damage over decades through a process called oxidative stress, which is the buildup of reactive oxygen molecules (also called free radicals) that chemically damage cellular components including DNA, proteins, and fats. By the time most people reach their 80s, mitochondrial efficiency in key tissues has declined substantially, contributing to fatigue, muscle loss, and cognitive slowing.
Genetics and Lifespan: How Much Control Do You Actually Have?
Genetics accounts for approximately 20 to 30 percent of the variation in human lifespan, according to estimates derived from decades of identical and fraternal twin studies conducted across multiple countries. This figure is meaningfully lower than many people expect. The remaining 70 to 80 percent of lifespan variation is attributed to lifestyle choices and environmental exposures, which gives most individuals significant agency over how long they live.
Several specific genes have been identified through large population studies as strongly associated with exceptional longevity:
| Gene | Primary Function | Longevity Relevance |
|---|---|---|
| FOXO3 | Cell cycle regulation, stress response | Variants linked to longer life across multiple ethnic populations |
| APOE | Lipid metabolism, brain health | The e2 variant reduces Alzheimer’s risk; e4 increases it |
| CETP | Cholesterol transport | Variants linked to higher HDL and greater lifespan in centenarians |
| SIRT1 | Metabolic regulation, DNA repair | Associated with caloric restriction benefits |
| TERT | Telomere maintenance | Controls cellular lifespan through chromosome cap preservation |
Centenarians, who are people who have reached 100 years or older, consistently show a cluster of genetic variants that appear to slow the onset of age-related diseases rather than preventing the fundamental biology of aging. Research from the New England Centenarian Study, based at Boston University and one of the world’s longest-running longevity research programs, shows that centenarians tend to remain healthier for longer periods and compress their period of morbidity (illness and disability) into a shorter window near the end of life rather than experiencing decades of progressive decline.
Lifestyle Behaviors Most Reliably Linked to Exceptional Longevity
The behaviors with the strongest evidence for extending healthy human life have been studied across large population cohorts for decades, and the findings are notably consistent across research groups.
- Avoiding tobacco: Nonsmokers live an average of 10 years longer than lifelong smokers, with the benefit extending to former smokers who quit even in middle age.
- Maintaining healthy body weight: A body mass index (BMI, a standardized measure of weight relative to height) between 18.5 and 24.9 is associated with the lowest all-cause mortality rates in large population studies.
- Regular physical activity: At least 150 minutes per week of moderate-intensity aerobic exercise is associated with approximately a 30 percent reduction in all-cause mortality.
- High-quality diet: Eating patterns rich in vegetables, legumes, whole grains, and nuts while limiting processed meat and refined sugars are consistently linked to lower cardiovascular disease and cancer rates.
- Adequate sleep: Adults who sleep 7 to 9 hours per night show lower rates of heart disease, metabolic disorders, and cognitive decline compared with those sleeping fewer than 6 hours or more than 9 hours.
- Strong social connections: Social isolation increases mortality risk by approximately 29 percent, an effect comparable to smoking 15 cigarettes per day, according to a widely cited 2015 meta-analysis published in Perspectives on Psychological Science.
- Controlled chronic stress: Prolonged psychological stress accelerates telomere shortening and elevates cortisol, which is a hormone that at chronically elevated levels damages cardiovascular, immune, and metabolic systems.
The concept of Blue Zones, a term coined by researcher Dan Buettner in collaboration with National Geographic, refers to five geographic regions where people live measurably longer than the global average. These regions are Sardinia (Italy), Okinawa (Japan), Nicoya (Costa Rica), Ikaria (Greece), and Loma Linda (California). Common lifestyle features across all five areas include plant-dominant diets, strong multigenerational social networks, moderate daily physical activity that is embedded in routines rather than scheduled as formal exercise, and a strong sense of purpose.
The Science of Longevity Research in 2025: What Labs Are Actually Pursuing
Longevity science has become a serious, well-funded discipline, with hundreds of millions of dollars flowing annually into academic laboratories and private biotech companies. Researchers at Harvard Medical School, the Salk Institute, Stanford, and the Mayo Clinic are investigating interventions that may genuinely extend healthy human life, and several promising drug classes are now in clinical trials.
Senolytic Drugs: Clearing Out Aged Cells
Senolytics are a class of experimental drugs designed to selectively destroy senescent cells, eliminating the inflammatory burden they create in aging tissue. A 2019 Mayo Clinic study demonstrated that a combination of the cancer drug dasatinib and the plant compound quercetin improved physical function and reduced frailty biomarkers in older adults. Multiple phase 2 clinical trials of senolytic compounds are currently underway in conditions including pulmonary fibrosis (lung tissue scarring), osteoarthritis (joint cartilage breakdown), and kidney disease associated with diabetes.
NAD+ Precursors: Restoring Cellular Energy Metabolism
NAD+ precursors have attracted both scientific attention and massive commercial interest. NAD+ (nicotinamide adenine dinucleotide) is a molecule essential for energy metabolism and DNA repair that declines significantly with age. Supplements including NMN (nicotinamide mononucleotide) and NR (nicotinamide riboside) are already being widely sold to consumers while simultaneously undergoing clinical investigation. Harvard geneticist David Sinclair has been among the most prominent public advocates for this line of research, though most scientists note that robust human evidence for lifespan extension remains limited as of 2025.
Rapamycin: The Drug That Extended Mouse Lifespans Late in Life
Rapamycin, a drug originally developed as an immunosuppressant (a medication that reduces immune system activity to prevent organ rejection after transplantation), has produced some of the most exciting lifespan extension results seen in animal research. A 2009 study in Nature showed that rapamycin extended median lifespan in mice by 9 to 14 percent even when treatment was started at an age equivalent to 60 human years. Human clinical trials are in early stages, and no large randomized study has yet confirmed lifespan extension in people, though interest among both researchers and aging-interested individuals is substantial.
Epigenetic Reprogramming: The Most Ambitious Frontier
Epigenetic reprogramming represents the most ambitious frontier in the field. Epigenetics refers to chemical modifications to DNA that regulate which genes are active, and these modifications shift in measurable and consistent ways as the body ages. Nobel Prize winner Shinya Yamanaka developed a method using four specific proteins, now widely called Yamanaka factors, to reprogram adult cells back to a younger, stem-cell-like state. Altos Labs (a company that raised more than $3 billion in startup funding) and the Salk Institute are both pursuing partial versions of this reprogramming in living organisms, attempting to reverse biological age without erasing the specialized identity of differentiated cells.
Could Humans Actually Reach 150? The Realistic Assessment
Reaching 150 years would require overcoming biological barriers that current science has not yet solved. The most fundamental challenge is not any single disease but the underlying systemic deterioration that makes the body progressively more fragile with each passing decade regardless of what diseases are prevented.
The probability of dying in any given year follows the mathematical pattern described by Gompertz Law, named after mathematician Benjamin Gompertz who published the observation in 1825. Under this law, the annual probability of death approximately doubles every 8 years after age 30. By age 110, the annual probability of death exceeds 50 percent, which is why no more than a handful of people in the entire world are alive at age 115 at any given time, regardless of how many people survive to 100.
For a human to reach 150, an intervention would need to fundamentally flatten or reset this mortality curve rather than merely delay it by a few years. Several theoretical pathways are under investigation:
| Intervention | Mechanism | Current Research Stage |
|---|---|---|
| Partial epigenetic reprogramming | Reverses age-related gene expression shifts | Animal models, very early human trials |
| Senolytic drug therapy | Removes senescent cells from tissues | Phase 2 clinical trials in several diseases |
| Telomere extension | Restores protective chromosome caps | Preclinical research stage |
| Lab-grown organ replacement | Replaces failing organs with bioprinted tissue | Limited clinical use for specific tissues |
| Caloric restriction mimetics | Replicates metabolic benefits of eating less | Some animal and early human studies |
| AI-assisted drug discovery | Identifies novel molecular targets | Actively deployed in research pipelines |
Most longevity researchers express qualified optimism but caution that no current or near-term intervention has demonstrated the ability to push maximum human lifespan significantly beyond 125 to 130 years even in the most favorable projections. Aging biology involves hundreds of interacting molecular pathways, and making progress on one often reveals new constraints in others.
What the Most Ambitious Researchers Believe About the Future
Some figures in longevity science hold genuinely provocative views about what may become biologically possible. Biogerontologist Aubrey de Grey, founder of the SENS Research Foundation (an organization focused on strategies for engineered negligible senescence, which is a scientific approach targeting all forms of accumulated biological damage that cause aging), has stated publicly that the first person to live to 1,000 years may already have been born. This position sits well outside mainstream scientific consensus and is not shared by most researchers in the field.
More mainstream researchers like Nir Barzilai at the Albert Einstein College of Medicine are leading efforts to formally establish aging as a treatable medical condition rather than an inevitable background process. Barzilai’s TAME trial (Targeting Aging with Metformin, a study examining whether the widely used diabetes drug metformin can delay age-related disease onset in otherwise healthy older adults) enrolled more than 3,000 participants aged 65 to 79. A successful outcome would have major regulatory implications by providing a framework for approving drugs that target aging itself rather than individual diseases.
The distinction between lifespan (total years lived) and healthspan (years spent in good health, free from significant disease and disability) is the most important conceptual divide in current longevity research. Most scientists believe that extending healthspan is more realistic in the near term and more valuable to individuals than simply adding additional years regardless of their quality. An intervention that keeps someone cognitively sharp and physically capable until 95 before a rapid decline is arguably more meaningful than one that adds 10 years of disability and dependence.
Measuring Biological Age: The Tools Changing Longevity Science
Scientists studying aging now have powerful tools to measure biological age (how old the body actually is at the cellular level) separately from chronological age (how many years a person has been alive). These tools have transformed what it means to study and potentially intervene in aging.
Epigenetic clocks are computational models that measure DNA methylation patterns, which are chemical tags on DNA that change with age in highly consistent ways across individuals. The Horvath Clock, developed by UCLA biostatistician Steve Horvath in 2013, can estimate a person’s biological age with meaningful accuracy. Research using these clocks has demonstrated that two people of the same chronological age can differ by 10 to 20 years in their biological age depending on lifestyle, environmental exposures, and genetics. This finding implies that biological aging is much more modifiable than previously understood.
Proteomic analysis (large-scale study of all proteins circulating in the body) is another rapidly advancing approach. A 2023 study published in Nature Aging measured more than 2,900 proteins in blood samples from thousands of participants and found that protein patterns shift dramatically in three distinct bursts: at approximately age 34, 60, and 78. This surprising finding suggests that aging does not progress as a smooth, continuous decline but instead accelerates in waves, which may help researchers identify the most effective timing windows for anti-aging interventions.
Ethics, Equity, and the Society That Extreme Longevity Would Create
Dramatically extended human lifespans would create challenges for American social institutions that current policy frameworks are not designed to handle. Retirement systems, healthcare infrastructure, housing markets, and wealth distribution would all face serious pressure if large numbers of people routinely lived to 120, 130, or 150 years.
The U.S. Social Security system, which was designed when average retirement lasted roughly 10 to 15 years, paid out approximately $1.4 trillion in benefits in 2023. If effective longevity treatments extended average retirement to 50 or 60 years, the mathematical foundation of the program would require fundamental restructuring through either substantially higher contributions, dramatically altered benefit structures, or both.
Access and equity represent perhaps the most serious ethical dimension of the longevity field. If the most effective anti-aging treatments cost tens of thousands of dollars per year, they would initially be available only to the wealthiest individuals, widening already significant gaps in health and power across society. Researchers, ethicists, and economists are increasingly examining these implications, and some argue that longevity treatments should be treated as public health priorities rather than luxury goods if they prove effective.
On the other side of the ledger, longer productive lifespans could bring genuine social benefits. Researchers, educators, artists, and physicians who typically reach peak expertise in their 50s and 60s could contribute for decades longer if they remained cognitively sharp and physically capable well into their 80s and 90s. The accumulated wisdom and institutional knowledge represented by those additional productive years could reshape fields in ways that are difficult to quantify but potentially significant.
Conclusion: What the Current Evidence Actually Points Toward
From the verified record of 122 years set by Jeanne Calment to the emerging science of epigenetic reprogramming and senolytic drug therapy, the story of human longevity is one of remarkable scientific progress combined with honest biological constraints. The field has confirmed that the human body does have limits rooted in cellular mechanics, telomere shortening, mitochondrial decline, and accumulated molecular damage, but has not yet established with precision exactly where the absolute ceiling sits or whether targeted interventions can meaningfully raise it.
Reaching 150 years remains beyond what any current or near-term intervention has demonstrated, and the therapies capable of such an outcome are still in early or preclinical stages. What is clear is that longevity science has matured into a serious, rigorously funded discipline attracting some of the most capable researchers in biology and medicine. The next 20 to 30 years will likely produce interventions that meaningfully extend healthy lifespan for millions of Americans, even as the most dramatic projections for triple-digit extensions remain speculative.
For anyone alive today, the most evidence-backed strategy for reaching exceptional old age remains straightforward: avoid smoking, maintain a healthy weight, exercise at least 150 minutes per week, prioritize sleep, cultivate strong social bonds, and manage chronic stress. These behaviors are not merely placeholders while better science arrives. They are the foundation on which every future longevity intervention will be built, and they remain the single most powerful levers available to most Americans right now.
FAQs
What is the maximum age a human has ever lived to?
The oldest verified human lifespan belongs to Jeanne Calment of France, who lived to 122 years and 164 days before her death in 1997. Her record has been independently investigated and confirmed by multiple research teams and remains the accepted scientific standard.
Is it possible for a human to live to 150 years old?
Reaching 150 years is not achievable with any currently known intervention and would require major breakthroughs in aging biology that scientists have not yet produced. Most mainstream longevity researchers place the theoretical biological ceiling somewhere between 120 and 150 years, and surpassing it would likely require practical applications of technologies like epigenetic reprogramming that are still in early research stages.
What is the current average life expectancy in the United States?
The average U.S. life expectancy is approximately 79.3 years as of 2024. This figure varies meaningfully by sex, with women averaging approximately 81 years and men approximately 76 years, as well as by geography, income, and access to healthcare.
What is a supercentenarian?
A supercentenarian is a person who has reached or surpassed the age of 110. Fewer than 100 people worldwide qualify as supercentenarians at any given time, making this one of the smallest and most age-extreme demographic groups that researchers formally track.
How much of your lifespan is determined by genetics?
Genetics accounts for roughly 20 to 30 percent of the variation in human lifespan, based on large twin studies conducted across multiple countries. The remaining 70 to 80 percent is driven by lifestyle choices and environmental factors, meaning most people have substantial influence over how long they live through their daily behaviors and exposures.
What is the Hayflick Limit and why does it matter for aging?
The Hayflick Limit describes the maximum number of times a human cell can divide, typically 50 to 70 times, before permanently stopping. Discovered by Leonard Hayflick in 1961, this limit exists because each cell division shortens the telomeres (protective caps on chromosomes), and critically short telomeres trigger the cell to stop dividing or die. The Hayflick Limit is one of the central biological mechanisms explaining why human tissues lose function over time.
What are Blue Zones and why do people who live there tend to live longer?
Blue Zones are five geographic regions where populations consistently live measurably longer than the global average: Sardinia (Italy), Okinawa (Japan), Nicoya (Costa Rica), Ikaria (Greece), and Loma Linda (California). Residents in all five areas share lifestyle patterns including plant-heavy diets, strong multigenerational social networks, regular moderate physical movement built into daily routines, and a clearly defined sense of purpose, all of which are independently linked to reduced mortality in research studies.
What is epigenetic reprogramming and could it reverse aging?
Epigenetic reprogramming involves resetting chemical modifications on DNA that control gene expression and that shift predictably as the body ages, potentially reversing the molecular signals of aging. Researchers at institutions including the Salk Institute and companies such as Altos Labs (which raised more than $3 billion in funding) are testing whether partial reprogramming can rejuvenate cells and tissues. Results in animal models are promising, but practical human applications remain years to decades away.
What are senolytic drugs and do they extend lifespan?
Senolytics are experimental drugs that selectively destroy senescent cells, which are aged cells that have permanently stopped dividing and release inflammatory molecules that damage surrounding tissue. A 2019 Mayo Clinic study showed that the senolytic combination of dasatinib and quercetin improved physical function in older adults. While senolytics have extended lifespan in animal models, they have not yet been shown to extend overall human lifespan in clinical trials.
What is Gompertz Law and how does it explain aging mortality?
Gompertz Law, described by mathematician Benjamin Gompertz in 1825, shows that the annual probability of death approximately doubles every 8 years after age 30. By the time a person reaches 110, their annual mortality probability exceeds 50 percent, which is why extremely few people survive to ages beyond 115 even in the healthiest populations on Earth.
What is NAD+ and why do researchers think it matters for aging?
NAD+ (nicotinamide adenine dinucleotide) is a molecule essential for cellular energy production and DNA repair that declines substantially with age. Lower NAD+ levels are associated with mitochondrial dysfunction, slower DNA repair, and accelerated cellular aging. Supplements like NMN and NR are designed to boost NAD+ levels, but as of 2025, robust human clinical evidence that these interventions extend lifespan remains limited despite significant commercial interest.
What is the TAME trial and what does it hope to prove?
The TAME trial (Targeting Aging with Metformin) is a clinical study led by Dr. Nir Barzilai at the Albert Einstein College of Medicine, enrolling over 3,000 participants aged 65 to 79. It tests whether the widely prescribed diabetes drug metformin can delay the onset of multiple age-related diseases in otherwise healthy older adults. A positive outcome would provide the first regulatory framework for treating aging itself as a legitimate drug target.
Can rapamycin extend human lifespan?
Rapamycin is an immunosuppressant drug that extended median lifespan in mice by 9 to 14 percent even when treatment began late in life, according to a landmark 2009 study published in Nature. Human clinical trials are in early stages, and no large randomized controlled trial has yet proven lifespan extension in people. Some researchers and physicians are experimenting with low-dose rapamycin protocols, but this remains off-label and not endorsed by major health authorities.
What is the difference between lifespan and healthspan?
Lifespan is the total number of years a person lives, while healthspan is the number of those years spent free from serious disease, disability, or significant cognitive decline. Most longevity researchers now prioritize extending healthspan over raw lifespan, arguing that adding high-quality years of function and independence is both more achievable and more valuable than simply extending total years regardless of health quality.
How much does social isolation actually affect how long you live?
Social isolation increases all-cause mortality risk by approximately 29 percent, according to a 2015 meta-analysis published in Perspectives on Psychological Science. Researchers found this effect to be comparable in magnitude to smoking 15 cigarettes per day, making chronic loneliness and social disconnection one of the most significant and underappreciated mortality risk factors in the United States.
What is an epigenetic clock and how accurately can it predict biological age?
An epigenetic clock is a computational model that measures DNA methylation patterns (chemical tags on DNA that shift consistently as a person ages) to estimate biological age independently of chronological age. The Horvath Clock, introduced in 2013 by UCLA biostatistician Steve Horvath, demonstrated that two people of the same chronological age can differ by 10 to 20 years in biological age based on their lifestyle, health history, and genetics. These clocks are now used in clinical research to measure whether anti-aging interventions are actually slowing cellular aging.
Are there any drugs proven to extend human lifespan as of 2025?
As of 2025, no drug has been proven in a large-scale randomized controlled human trial to extend overall lifespan. Metformin, rapamycin, NAD+ precursors, and various senolytic compounds are under active investigation. A significant barrier is that the U.S. regulatory system does not yet have a defined pathway for approving a drug whose primary indication is slowing aging rather than treating a specific disease.
At what ages does biological aging accelerate the most?
A 2023 study in Nature Aging that analyzed more than 2,900 blood proteins in thousands of participants identified three distinct waves of accelerated biological aging: at approximately age 34, 60, and 78. This finding challenged the assumption that aging is a smooth and continuous process, suggesting instead that it progresses in discrete bursts that may represent opportunities for targeted intervention.
What is the SENS Research Foundation and what does it believe about human longevity?
The SENS Research Foundation (Strategies for Engineered Negligible Senescence Research Foundation) is an organization founded by biogerontologist Aubrey de Grey that focuses on identifying and eliminating all forms of accumulated biological damage that drive aging. De Grey has argued that the first person to live to 1,000 years may already be alive today, a position that is far outside mainstream scientific consensus but reflects the most extreme optimistic view within the longevity research community.
What role does exercise play in extending lifespan?
Regular physical activity at a minimum of 150 minutes per week of moderate-intensity exercise is associated with approximately a 30 percent reduction in all-cause mortality across large epidemiological studies. Exercise improves lifespan prospects through multiple pathways including reduced cardiovascular disease risk, better insulin sensitivity, lower cancer rates, and evidence that it slows telomere shortening in immune cells, suggesting a direct effect on the pace of cellular aging.